Anti-Human Complement C5 Reference Antibody (Crovalimab, RUO)
- Catalog number: BS10321
- Availability: In Stock
$176.00
- Ex Tax: $176.00
Description: Crovalimab (BS10321) is a research-grade recombinant antibody targeting CPAMD4. Produced in mammalian cells with native-like glycosylation.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Humanized
Isotype: IgG1-kappa
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: CPAMD4,C5,C3andPZP-likealpha-2-macroglobulindomain-containingprotein4,ComplementC5
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: RG-6107,RO7112689,SKY-59,CAS:1917321-26-6
Background: Complement C5 is a ~188 kDa protein. Precursor of the C5a anaphylatoxin and complement C5b components of the complement pathways, which consist in a cascade of proteins that leads to phagocytosis and breakdown of pathogens and signaling that strengthens the adaptive immune system. Activated downstream of classical, alternative, lectin and GZMK complement pathways.
References:
1. Rawal, N. et al. (2003) The Journal of biological chemistry 278, 38476-83. PMID: 12878586
2. Rawal, N. et al. (2008) The Journal of biological chemistry 283, 7853-63. PMID: 18204047
3. Heesterbeek, DA. et al. (2019) The EMBO journal 38. PMID: 30643019
4. DiScipio, RG. et al. (1983) The Journal of biological chemistry 258, 10629-36. PMID: 6554279
5. Donado, CA. et al. (2025) Nature 641, 211-221. PMID: 39914456
6. Lan, F. et al. (2025) Nature 638, 490-498. PMID: 39814882
Note: For research use only. Not suitable for clinical or therapeutic use.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Humanized
Isotype: IgG1-kappa
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: CPAMD4,C5,C3andPZP-likealpha-2-macroglobulindomain-containingprotein4,ComplementC5
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: RG-6107,RO7112689,SKY-59,CAS:1917321-26-6
Background: Complement C5 is a ~188 kDa protein. Precursor of the C5a anaphylatoxin and complement C5b components of the complement pathways, which consist in a cascade of proteins that leads to phagocytosis and breakdown of pathogens and signaling that strengthens the adaptive immune system. Activated downstream of classical, alternative, lectin and GZMK complement pathways.
References:
1. Rawal, N. et al. (2003) The Journal of biological chemistry 278, 38476-83. PMID: 12878586
2. Rawal, N. et al. (2008) The Journal of biological chemistry 283, 7853-63. PMID: 18204047
3. Heesterbeek, DA. et al. (2019) The EMBO journal 38. PMID: 30643019
4. DiScipio, RG. et al. (1983) The Journal of biological chemistry 258, 10629-36. PMID: 6554279
5. Donado, CA. et al. (2025) Nature 641, 211-221. PMID: 39914456
6. Lan, F. et al. (2025) Nature 638, 490-498. PMID: 39814882
Note: For research use only. Not suitable for clinical or therapeutic use.
Images
-
BioactivitySEC-HPLC detection for Research Grade Crovalimab.
